Abstract A growing body of evidence suggests that targeting low-density lipoprotein cholesterol is not enough and that a substantial residual risk remains despite aggressive statin treatment, particularly in patients with mixed dyslipidemia. Statin plus fibrate combination results in a more effective control of several lipid parameters than either monotherapy with a safety profile similar to both monotherapies. Therefore, this combination might represent a therapeutic option for selected patients with mixed dyslipidemia. However, the clinical benefit of statin/fibrate combination has only been observed in small subgroup analyses and more data are needed before a wider implementation is recommended in everyday clinical practice.